If you have PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and you just completed your first cycle of lutetium Lu-177 vipivotide tetraxetan, you may notice that your bone pain feels worse in the days that follow. This is called a pain flare. It can be a difficult early side effect of Lu-177 PSMA therapy, because pain is what you were hoping to reduce, not increase. But a pain flare is usually short-lived. For many patients, it is a sign that the therapy has reached its target.
What is a pain flare?
A pain flare is a temporary increase in bone pain that some patients feel within the first week after a Lu-177 PSMA infusion. The pain typically builds in the first few days after the infusion and then eases on its own. For most patients who experience one, the discomfort peaks around day 3 to 7 and fades within one to two weeks.
A pain flare can feel alarming when you are already living with bone pain from metastases. But it is a known response to radioligand therapy that your care team can help you plan for and manage safely at home.
Why does a pain flare happen after Lu-177 PSMA therapy?
Lutetium Lu-177 vipivotide tetraxetan (sold under the brand name Pluvicto) works by binding to PSMA (prostate-specific membrane antigen) proteins on the surface of prostate cancer cells. Once attached, the lutetium-177 isotope delivers targeted beta radiation directly into those cells, disrupting and killing them from the inside.
That process triggers a brief inflammatory response in the tissue surrounding the treated tumor. In men with bone metastases, this inflammation happens inside the bone itself. The result is temporary swelling and increased pressure around the metastatic site. That pressure on bone and nearby nerve endings is what you feel as heightened pain during a flare.
Think of it this way: the therapy has found its target and is active. The flare is your body's initial response to that activity. It does not mean the cancer is spreading.
For a full explanation of how the therapy works at the cellular level, see our article on how Lu-177 PSMA targets PSMA-expressing cells and what theranostics means for mCRPC.
How common is a pain flare?
Pain flares do not happen to every patient. Rates vary depending on how flares are defined and tracked, but flare-related bone pain is consistently identified as a known and manageable side effect. The best practice guidance for PSMA-targeted radiopharmaceutical therapy specifically notes that bone pain flares are a side effect that care teams should prepare patients for before the first cycle.
You are more likely to experience a notable flare if:
- You already have significant bone metastases before your first cycle
- Your existing bone pain is moderate to severe before treatment starts
- Your PSA was elevated and rising quickly before therapy began
If your bone pain before starting therapy was mild, your risk of a strong flare is lower - though not zero. Some patients with a heavy bone metastatic burden notice a more pronounced flare than those with fewer affected sites.
What does a pain flare feel like?
Most patients describe a pain flare as a worsening of the bone pain they were already experiencing. If your lower back aches from a lumbar metastasis, the flare may make that ache feel sharper. If your hips or pelvis are tender, they may feel more sore. Some patients describe a flu-like aching across the skeleton in the first few days after the infusion.
A typical pain flare is:
- Concentrated in areas where bone metastases are already known
- Temporary - lasting days in most cases, not weeks
- Manageable with the pain strategies your care team recommends
- Self-limiting - it does not keep escalating
Keeping a brief daily pain log in the first two weeks after each cycle can help. Rate your pain on a simple 0-to-10 scale and note the date. This gives your team useful information and helps you see clearly when the pain starts to ease.
Does a pain flare mean the treatment is working?
This is one of the most common questions patients ask after their first cycle. The honest answer is: a flare may be a positive indicator, but it is not a reliable measure of response on its own.
Research indicates that patients who experience a flare after the first cycle are among those who go on to respond well. This makes sense because a flare may indicate the therapy found PSMA-expressing lesions and delivered enough radiation to trigger a cellular response. But a pain flare alone does not confirm that the treatment is controlling the disease. Having no flare does not mean the therapy has failed.
Response to Lu-177 PSMA therapy is assessed through PSA trends, PSMA-PET imaging, CT scans, and patient-reported outcomes across multiple cycles - not through a single symptom in week one. If you want an independent expert review of how your imaging and response markers are being interpreted, you can send your scans to the Art of Healing Cancer team for review before or during your treatment course.
How is a pain flare managed?
Pain flares are manageable. Your care team should give you a clear plan before you leave the treatment center after your first infusion. Based on the joint EANM/SNMMI procedure guideline for Lu-177 PSMA radioligand therapy, here is what management generally looks like:
- Keep taking your existing pain medicines - Your regular pain medicines are the first line of defense during a flare. Do not stop or reduce them without your care team's guidance.
- Rest and limit strenuous activity - Physical strain can worsen inflammation in already-sensitive bone. Low-impact movement is generally fine; heavy lifting or high-impact exercise should wait until the flare settles.
- Stay well hydrated - Drinking plenty of fluids is already recommended after a Lu-177 PSMA infusion to support kidney and bladder clearance of the radioactive agent. Good hydration also supports general recovery during a flare.
- Short-course anti-inflammatory medicines - The EANM/SNMMI guideline notes that anti-inflammatory drugs, including short courses of corticosteroids in certain cases, may reduce swelling and pain around flaring lesions. Your doctor will determine what is appropriate for your situation. Do not start any new medicine without talking to your care team first.
- Plan ahead before your first cycle - The best time to agree on a pain management strategy is before the infusion, not after the flare has started. Ask your nuclear medicine team what they recommend for the first week at home, and make sure you have what you need in place before you leave the clinic.
The EANM/SNMMI guideline also notes that anti-inflammatory coverage may be especially important for patients with metastases near the spinal cord or other sensitive locations, where swelling could affect nerve function. Your team should assess this individually before your first cycle.
Pain flare and fatigue often arrive together
A pain flare frequently comes alongside a general dip in energy. Many patients feel drained for several days after the infusion - a combination of the body's response to radiation, the local inflammatory process, and disrupted sleep caused by increased discomfort at night.
Fatigue was the most commonly reported side effect in the VISION trial (the phase 3 study that led to FDA approval of lutetium Lu-177 vipivotide tetraxetan in March 2022), affecting 43.1 percent of patients who received the therapy. Not all of this was tied to flare reactions, but the overlap in the first week after infusion is common enough that you should plan for both at once.
Poor sleep makes pain feel worse. If discomfort at night is disrupting your rest during the first week after a cycle, let your care team know - they may be able to adjust your pain management plan for evening hours. Some patients also use supplements for bone support during treatment. If you are interested, the Joint and Bone range at Ayurnomics is one option. Always discuss any supplement with your oncologist before using it during active treatment.
For more on managing energy throughout your treatment course, see our article on managing fatigue during and after Lu-177 PSMA therapy.
Will a pain flare happen after every cycle?
For most patients, the first cycle produces the most noticeable flare response - if one occurs at all. By the second and third cycle, two things have typically changed:
- The tumor burden in bone may have begun to reduce, meaning there is less tissue mounting a flare response
- Your care team and you are better prepared - any flare that does occur tends to be caught and managed more quickly
Many patients report that their overall bone pain actually improves over the course of treatment. The VISION trial, published in the New England Journal of Medicine, found that lutetium Lu-177 vipivotide tetraxetan significantly delayed worsening of pain and extended the time to pain deterioration compared to standard care alone. A temporary first-cycle flare does not predict how the rest of your treatment course will unfold.
To understand what your team will be tracking across cycles and what decisions come next, see the article on what to monitor after your Lu-177 PSMA cycles and how to plan follow-up care.
When a pain increase may need urgent attention
Most pain flares ease on their own within one to two weeks. But some symptoms after a Lu-177 PSMA infusion warrant prompt contact with your care team. Do not wait to see if they improve on their own if you notice:
- New weakness, numbness, or tingling in your legs, arms, or hands
- Any loss of bladder or bowel control
- Pain that is sharply worsening rather than peaking and beginning to ease
- Fever alongside increased bone pain
- Pain appearing in a new location, not an area where metastases were already known
These symptoms could point to complications separate from a routine flare (including, in rare cases, pressure on the spinal cord from a lesion that has swollen near the spine). This is uncommon, but it requires quick assessment. If you develop new neurological symptoms at any point after an infusion, go to the nearest emergency department and tell the team you have recently received radioligand therapy.
When to talk to your doctor
Speak with your nuclear medicine team or oncologist before your first cycle to agree on a pain management plan for the first week at home. Contact them during the first week after treatment if your pain rises sharply, is not controlled by your usual medicines, or if you develop any new neurological symptoms. Always report a pain flare - even one you managed comfortably - so it can be documented and factored into planning for future cycles.
If you have not yet started treatment and want a pre-treatment eligibility review or a second opinion on your care plan, you can submit your case through the Lutetium Therapy contact form. If Lu-177 PSMA is not the right option for your situation, the team can also advise on what alternatives may be available.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How long does a pain flare last after a Lu-177 PSMA cycle?
Most pain flares peak within 3 to 7 days after the infusion and ease within one to two weeks. In patients who respond well to treatment, bone pain levels often fall below what they were before treatment started by the time of the second cycle. If your pain has not started to improve after 10 to 14 days, let your care team know.
Does a pain flare mean my cancer is getting worse?
Not necessarily. A pain flare is caused by a brief inflammatory response around tumor cells as they absorb the targeted radiation from lutetium Lu-177 vipivotide tetraxetan. It does not indicate that cancer is spreading to new areas. Some research suggests that a flare after the first cycle may actually be associated with tumor response, though response is confirmed through imaging and PSA trends over multiple cycles, not by the presence of a flare alone.
Can I take pain medicine for a flare without asking my doctor first?
You should always check with your care team before adding any new medicine, even over-the-counter options, during Lu-177 PSMA therapy. Some pain medicines can affect kidney function or interact with other treatments you may be taking. Your team should give you a specific pain management plan for the first week after each infusion before you leave the clinic - the goal is to have that plan ready before a flare starts, not after.
Will a pain flare happen after every cycle?
For most patients, the first cycle produces the most noticeable flare - if one occurs at all. Subsequent cycles tend to cause less of a flare response, partly because the tumor burden in bone may be reducing over time. Many patients report that their overall bone pain improves across the full course of treatment.
When should I go to the emergency department rather than calling my care team?
Seek emergency care immediately if you develop new weakness, numbness, or tingling in your legs or arms, any loss of bladder or bowel control, or pain that is severe and not controlled by any of your current medicines. Tell the emergency team that you have recently received radioligand therapy. These symptoms can indicate a complication, such as pressure on the spinal cord, that requires rapid assessment.
Is a pain flare the same as cancer progression?
No. A pain flare is a short-term side effect that occurs in the first week or two after an infusion. Cancer progression is a longer-term change assessed through imaging and blood markers over months. A temporary increase in bone pain in the first week after an infusion is an expected reaction in some patients and does not mean the disease is advancing.
